外用钙调神经磷酸酶抑制剂使用与癌症风险关联的系统综述与Meta分析
该系统综述与Meta分析纳入8项队列研究和3项病例对照研究,评估外用钙调神经磷酸酶抑制剂(TCI)与癌症风险关联。结果显示TCI使用与总体癌症风险无显著关联(RR 1.03),但淋巴瘤风险升高(非活动对照RR 1.86,外用糖皮质激素对照RR 1.35),未发现皮肤癌风险增加。
要点
- TCI使用与总体癌症风险无显著关联(RR 1.03,95%CI 0.92-1.16)。
- TCI使用与淋巴瘤风险升高相关,非活动对照RR 1.86,外用糖皮质激素对照RR 1.35。
- 未发现TCI使用与黑色素瘤或角化细胞癌风险增加显著关联。
核心结论
- TCI使用与淋巴瘤风险升高相关,但与总体癌症及其他癌症无显著关联。
- 个体因TCI使用增加的淋巴瘤绝对风险可能非常小。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、Embase和Web of Science至2020年8月21日。
- 采用随机效应Meta分析计算合并相对危险度(RR)。
主要发现
- 与不活动对照相比,TCI使用与总体癌症风险无关联(RR 1.03;95%CI 0.92-1.16)。
- 淋巴瘤风险在非活动对照(RR 1.86;95%CI 1.39-2.49)和外用糖皮质激素对照(RR 1.35;95%CI 1.13-1.61)中均升高。
- 未发现TCI使用与黑色素瘤和角化细胞癌风险增加显著关联。
临床怎么用
- 临床使用TCI时需权衡淋巴瘤潜在风险,但个体绝对风险很低。
- 对需长期使用TCI的患者,可告知总体癌症风险未显著增加但淋巴瘤风险略有升高。
局限性
- 纳入研究为观察性设计,可能存在残余混杂。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Topical calcineurin inhibitors (TCIs) are commonly used as second-line treatment for atopic dermatitis. In 2006, the US Food and Drug Administration issued a black box warning against TCI use, citing data from case reports and animal studies indicating a potential risk of cancer. OBJECTIVE: To evaluate the association between TCI use and risk of malignant neoplasms compared with nonactive and active comparator groups. DATA SOURCES: Electronic searches were conducted in MEDLINE via Ovid, Embase via Ovid, and Web of Science from database inception to August 21, 2020. STUDY SELECTION: Observational studies investigating the association between treatment with TCIs (ie, tacrolimus and pimecrolimus) and the development of cancer with nonactive or active comparators were included. The population of interest was not limited to any specific disease state, age, or sex. All articles were assessed independently and in duplicate by 2 reviewers. Risk of bias was assessed using the Newcastle-Ottawa scale. Of 2464 nonduplicate records retrieved from the search, 11 studies met the inclusion criteria. DATA EXTRACTION AND SYNTHESIS: Data extraction was conducted independently by 2 reviewers according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Random-effects meta-analyses were used to derive pooled relative risk (RR) estimates. Data were analyzed from July 25 to October 25, 2020. MAIN OUTCOMES AND MEASURES: Risk of cancer overall and risk of specific cancer types (lymphoma, melanoma, and keratinocyte carcinoma). RESULTS: Eight unique cohort studies (408 366 treated participants [55.1% female], 1 764 313 nonactive comparator controls, and 1 067 280 controls using topical corticosteroids) and 3 unique case-control studies (3898 cases [55.0% male] and 14 026 cancer-free controls [52.4% male]) were included. There was no association between TCI use and cancer overall compared with nonactive comparators (RR, 1.03; 95% CI, 0.92-1.16). Lymphoma risk was elevated with TCI use with both nonactive (RR, 1.86; 95% CI, 1.39-2.49) and topical corticosteroid comparators (RR, 1.35; 95% CI, 1.13-1.61). No significant association was found between TCI use and increased skin cancer (melanoma and keratinocyte carcinoma). CONCLUSIONS AND RELEVANCE: The findings of this systematic review and meta-analysis suggest an association between TCI use and risk of lymphoma but not other cancers. Combined with the low absolute risk of lymphoma, the potential increased risk attributable to TCI use for any individual patient is likely very small.
引用
- Lam M, Zhu JW, Tadrous M, et al. Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-analysis. JAMA Dermatol. 2021. PMID: 33787818. doi:10.1001/jamadermatol.2021.0345
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。